
A prospective study evaluated the efficacy and safety of switching from entecavir (ETV) to tenofovir alafenamide (TAF) in CHB patients with low-level viremia (LLV). Among 351 patients from eight hospitals, those who switched to TAF had significantly higher complete virological response (75.3% vs. 11.4%, P < 0.001) and ALT normalization rates (67.8% vs. 17.1%, P < 0.001) at 48 weeks compared to those continuing ETV. Renal safety and lipid profiles were comparable between groups, supporting TAF as a superior alternative for LLV management.
Like
Save
Share